Global
Austria
Japan
Belgium
Brazil
Netherlands
Portugal
Czech Republic
Spain
Denmark
Sweden
France
Germany
Taiwan
Ireland
United Kingdom
Italy
During the Thrombosis & Hemostasis Summit of North America 2020 Virtual Conference, we presented new data from a post-hoc analysis of the ENVISION Phase 3 study of GIVLAARI® (givosiran), evaluating hemin use in patients with acute hepatic porphyria. We also presented encore data evaluating healthcare...
New data from a post-hoc analysis of the ENVISION Phase 3 study of GIVLAARI® (givosiran) were presented during the American College of Gastroenterology 2020 Virtual Annual Scientific Meeting, evaluating outcomes in patients with acute hepatic porphyria with or without prior hemin prophylaxis. Findings on healthcare...
We presented progress on our RNAi therapeutics platform efforts at the Oligonucleotide Therapeutics Society (OTS) 2020 Annual Meeting. Akinc et al. – “ALN-COV: An Investigational RNAi Therapeutic for COVID-19” Brown et al. – “Evidence for an Intracellular Depot that Contributes to the Extended Duration of Activity of...